A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-03-31

Study Completion Date

2005-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary: To determine factors that affect absorption and serum levels of lycopene after supplementation.

Secondary:

1. To evaluate general safety and tolerability of oral lycopene 15 or 30 mg per day for 12 weeks.
2. To determine lycopene effects on reducing serum levels of prostate specific antigen (PSA) and on relieving lower urinary tract symptoms (LUTS) in relation to prostate hypertrophy as evaluated by the International Prostate Symptom Score (I-PSS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Lycopene on High Risk Prostatic Tissue

NCT01443026

Intraepithelial Prostatic Neoplasia Prostatic Neoplasms

COMPLETED PHASE2

A Study to Evaluate the Effects of a Prostate Health Formulation

NCT02886832

Prostate Health

COMPLETED NA

Drug Use Investigation for AVOLVE(BPH)

NCT01376284

Prostatic Hyperplasia

COMPLETED

The Evaluation of Banana Flower Stamens Extract on Prevention of Benign Prostatic Hyperplasia in Adults

NCT04266418

Benign Prostatic Hyperplasia (BPH)

RECRUITING NA

Effects of Isoflavone in Patients With Watchful Waiting Benign Prostate Hyperplasia

NCT00861588

Benign Prostate Hyperplasia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an uncontrolled intervention study in which eligible male subjects (N=60), after a two-week washout, will be randomized to receive lycopene either 15 or 30 mg per day for 12 weeks. About equal numbers of subjects will be randomized to either 15 or 30 mg of lycopene (about 30 subjects for each arm). The study is expected to be finished in 2 year. The study is expected to be finished in 2 year. Concerning an expected dropout rate of 10%, 66 subjects will be recruited for the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

BPH

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Lycopene 15 mg/day

Group Type EXPERIMENTAL

Lycopene

Intervention Type DRUG

A: Lycopene15 mg/day ; B: Lycopene30 mg/day

B

Lycopene 30 mg/day

Group Type EXPERIMENTAL

Lycopene

Intervention Type DRUG

A: Lycopene15 mg/day ; B: Lycopene30 mg/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lycopene

A: Lycopene15 mg/day ; B: Lycopene30 mg/day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male subjects aged 40 or older with no pathologically-proven prostate cancer or other cancers. Patients who have had a negative prostate biopsy are still acceptable.
* Subjects with a PSA between 2.5 and 20.0 ng/ml.
* Subjects understand the study procedures and agree to participate in the study by providing a written informed consent and scheduled blood or urine samples.
* Subjects whose liver function and renal function tests are within normal range.

Exclusion Criteria

* Subjects who may have fluctuated serum PSAs, such as urinary tract infection, prostatitis, acute urinary retention, receiving radiotherapy to the pelvis, etc.
* Subjects who have received a prostate surgery or biopsy within 6 weeks before the initiation of lycopene supplementation.
* Subjects who may or will receive a prostate surgery or biopsy within 12 weeks of the initiation of lycopene supplementation.
* Subjects who have known allergic reaction to carotenoids including lycopene.
* Subjects who are participating or will participate in other clinical trials.
* Subjects who are taking medications that may alter serum PSA levels, such as 5-alpha reductase inhibitor (eg. finasteride), sex steroids or hormonal agents (eg. luteinizing hormone releasing hormone agonists, cyproterone acetate, flutamide, bicalutamide, megesterol acetate, etc.).
* Subjects who may require increased dosage of medications for lower urinary tract symptoms (LUTS) during the 12 weeks of protocol treatment. Subjects who have been put on medications for LUTS before entry and have a stabilized disease are still acceptable. These medications include, but note limited to, selective or non-selective alpha-blockers and anti-cholinergics.
* Subjects who have or have had clinical gastrointestinal malabsorption regardless of the etiology.

Minimum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No